Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.3%

61 terminated/withdrawn out of 1410 trials

Success Rate

92.5%

+6.0% vs industry average

Late-Stage Pipeline

17%

234 trials in Phase 3/4

Results Transparency

2%

14 of 752 completed trials have results

Key Signals

124 recruiting14 with results31 terminated30 withdrawn

Enrollment Performance

Analytics

N/A
624(60.4%)
Phase 4
195(18.9%)
Phase 2
135(13.1%)
Phase 1
40(3.9%)
Phase 3
39(3.8%)
1033Total
N/A(624)
Phase 4(195)
Phase 2(135)
Phase 1(40)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1410)

Showing 20 of 1410 trials
NCT05887466Phase 1Completed

Study to Evaluate the Safety and Efficacy of ESC-derived Dopamine Progenitor Cell Therapy in PD Patients

Role: collaborator

NCT07525869Not ApplicableRecruiting

An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy

Role: lead

NCT07515859Completed

Risk Stratification of Cancer Therapy-Related Cardiac Dysfunction Using AI-Enhanced Electrocardiography

Role: lead

NCT07524101Not ApplicableNot Yet Recruiting

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

Role: lead

NCT07507188Phase 2Not Yet Recruiting

Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)

Role: lead

NCT07506629Not ApplicableNot Yet Recruiting

Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty

Role: lead

NCT07495293Phase 1Not Yet Recruiting

Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer

Role: lead

NCT07477548Phase 2Not Yet Recruiting

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Role: lead

NCT07471867Phase 4Not Yet Recruiting

Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention

Role: lead

NCT07469683Phase 2Recruiting

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Role: lead

NCT07467174Phase 4Not Yet Recruiting

RCT Comparing Reduced-port Robotic and Conventional Laparoscopic Subtotal Gastrectomy

Role: lead

NCT07450989Not ApplicableRecruiting

Effects of Hip-Assist Exoskeleton Torque on Gait Parameters

Role: lead

NCT07432516Not ApplicableNot Yet Recruiting

Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial

Role: lead

NCT07432269Not Yet Recruiting

A Prospective, Controlled, Single-Center Confirmatory Study to Evaluate the Accuracy and Safety of Core Temperature Measurement Using the XST600 Electronic Thermometer Compared to the 3M SpotOn Thermometer in Adult Patients

Role: lead

NCT07418294Recruiting

Fluctuational Imaging for the Diagnosis of Hepatic Hemangioma: A Multicenter, Prospective Study

Role: lead

NCT06677970Phase 3Recruiting

Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)

Role: lead

NCT04603248Not ApplicableActive Not Recruiting

A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Role: lead

NCT05682118Not ApplicableRecruiting

Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve

Role: lead

NCT05280457Phase 2Recruiting

HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy

Role: lead

NCT05286060Phase 2Active Not Recruiting

Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer

Role: lead